Stockscreener 앱 받기
2.51
5.46%
0.13
시간 외 거래:
2.50
-0.010
-0.40%
전일 마감가:
$2.38
열려 있는:
$2.38
하루 거래량:
1.22M
Relative Volume:
1.14
시가총액:
$322.89M
수익:
$564.17M
순이익/손실:
$37.03M
주가수익비율:
22.92
EPS:
0.1095
순현금흐름:
$-24.46M
1주 성능:
+11.06%
1개월 성능:
-4.92%
6개월 성능:
-37.25%
1년 성능:
-42.03%
1일 변동 폭
$2.35
$2.51
1주일 범위
$2.225
$2.5597
52주 변동 폭
$2.21
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
명칭
Organogenesis Holdings Inc
전화
781-575-0775
주소
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.51 | 306.16M | 564.17M | 37.03M | -24.46M | 0.1095 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Lake Street | Buy |
| 2024-02-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-08-26 | 재개 | Credit Suisse | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
| 2019-04-17 | 개시 | Oppenheimer | Outperform |
| 2019-04-11 | 개시 | SunTrust | Buy |
모두보기
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
3 Penny Stocks With Market Caps Under $400M To Consider - simplywall.st
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens - FinancialContent
Organogenesis shares jump 20% following positive clinical trial results - MSN
What's going on with Organogenesis stock on Wednesday? - MSN
Options Flow: Will Organogenesis Holdings Inc benefit from rate cuts2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
720p-h264Dailyhunt - Dailyhunt
What's Going On With Organogenesis Stock On Wednesday? - Sahm
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight (NASDAQ:ORGO) - Seeking Alpha
Organogenesis stock rockets after diabetic foot ulcer trial posts statistically significant win - MSN
PuraPly AM Triumphs in Wound Healing Trial, Paves Way for New Successes - StocksToTrade
Organogenesis’ Clinical Trials Propel Stock Amid FDA Progress - timothysykes.com
Organogenesis stock surges 20% on trial results By Investing.com - Investing.com Australia
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win - Benzinga
Organogenesis stock surges 20% on trial results - Investing.com
Organogenesis stock up as PuraPlyAM succeeds (ORGO:NASDAQ) - Seeking Alpha
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 - Bitget
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com Canada
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPlyAM - Bitget
ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment - Stocktwits
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM - The Manila Times
In 170-patient diabetic foot ulcer study, Organogenesis clears key goal - Stock Titan
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain - Bitget
Organogenesis Cleared to Begin Rolling BLA for ReNu Knee Osteoarthritis Therapy - marketscreener.com
Regenerative medicine giant Organogenesis Holdings Inc (ORGO) recently announced the successful completion of a key meeting with the U.S. Food and Drug Administration (FDA). - Bitget
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain - The Manila Times
Knee pain treatment for 31 million Americans moves toward FDA filing - stocktitan.net
New York real estate firm acquires Organogenesis property for $68M - Providence Business News
ORGO SEC FilingsOrganogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Movement Recap: Whats the fair value of Organogenesis Holdings Inc stockQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Published on: 2026-03-31 10:52:09 - baoquankhu1.vn
IPO Launch: Is Organogenesis Holdings Inc impacted by rising rates2026 Historical Comparison & High Conviction Buy Zone Alerts - baoquankhu1.vn
Dividend Watch: Whats the fair value of Organogenesis Holdings Inc stock2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Organogenesis Facing Hard Times As It Adjusts To CMS Rule Changes (NASDAQ:ORGO) - Seeking Alpha
Asia Pacific Wound Care Biologics Market Projected to Witness - openPR.com
Organogenesis (NASDAQ:ORGO) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates Buy Rating and $8 Price Target for ORGO | ORGO S - GuruFocus
Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO - MarketBeat
Income Plays: Is Organogenesis Holdings Inc benefiting from innovation trendsDividend Hike & Target Return Focused Picks - baoquankhu1.vn
Aug Summary: Is Organogenesis Holdings Inc impacted by rising ratesWatch List & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Trading Recap: How does Organogenesis Holdings Inc correlate with Nasdaq2026 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Organogenesis Holdings Inc (ORGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.06%
1.05%
자본화:
|
볼륨(24시간):